Sunrise completes $11.8 million placement:
This article was originally published in Clinica
Sunrise Technologies International has completed an $11.8 million private placement at $3.50 per share. The Fremont, California-based company will use the funds to help it to gain pre-market approval for laser products for the treatment of hyperopia, to plan the launch of the Sunrise Hyperion LTK system - an office based instrument which uses two rings of laser energy - and to continue product development.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.